Humed technologies, inc. email format

HuMed Technologies (HuMed) is a cancer support products company passionately motivated to improve patient quality of life by developing products that alleviate adverse effects of cancer treatment. The first two products are a few short years from the market for the treatment of the very painful mouth sores known as oral mucositis (OM). OM dramatically impacts a large number of cancer patients: OM plagues 30-40% of the 1.8 million Americans who are diagnosed with cancer each year and directly impacts their treatment success. This is currently a $500M market with a CAGR of ~8.0% over 5 years; this limited size is due to a lack of products that adequately address the need. Among the 71,500 new US head and neck cancer patients each year, 100% of the patients who receive altered fractionation radiation treatment suffer from OM. This radiation is the standard treatment in most of the US. Fully 60-70% of these head and neck patients require hospitalization for the intense, debilitating pain from their mouth sores and often require feeding tubes. This interrupts and/or reduces their therapy and the success of their cancer treatment, ultimately affecting their survival. There are 18 million cancer patients globally. 40% on chemotherapy get OM and 100% of those on radiation. For the 709,000 H&N cancer patients, again 60%-70% need hospitalization just because of OM. HuMed’s first product is an innovative oral rinse expecting a speedy path to market with a 510(k) clearance in as soon as 22 months. It will be the only mouthwash on the market that visibly shows surface coverage in the oral mucosa (surface tissue of the mouth) using a colored, patented technology. Specifically, curcumin is used as a natural colorant and delivered in controlled amounts with HuMed’s proprietary platform technology. This product is expected to require fewer applications, increase patient and oncologist (Dr.) confidence and reduce the compliance issues of most barrier rinse products.